Bernard P. Murray

JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib

Paqui G. Través, Bernard P. Murray, Federico Campigotto et al. · Annals of the Rheumatic Diseases · 2021 · 333 citations · Full text

Medicine, Internal Medicine, Pharmacology +16

Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat

Eve‐Irene Lepist, Xuexiang Zhang, Hao Jia et al. · Kidney International · 2014 · 244 citations · Full text

Medicine, Nephrology, Pharmacology +17

Pharmacokinetics and Pharmacodynamics of GS-9350: A Novel Pharmacokinetic Enhancer Without Anti-HIV Activity

Anita Mathias, Polina German, Bernard P. Murray et al. · Clinical Pharmacology & Therapeutics · 2009 · 208 citations

Medicine, Pharmacokinetics, Pharmacology +15

Cobicistat (GS-9350): A Potent and Selective Inhibitor of Human CYP3A as a Novel Pharmacoenhancer

Lianhong Xu, Hongtao Liu, Bernard P. Murray et al. · ACS Medicinal Chemistry Letters · 2010 · 200 citations

Medicine, Medicinal Chemistry, Pharmacology +14

Cobicistat Boosts the Intestinal Absorption of Transport Substrates, Including HIV Protease Inhibitors and GS-7340, <i>In Vitro</i>

Eve‐Irene Lepist, Truc K. Phan, Anupma Roy et al. · Antimicrobial Agents and Chemotherapy · 2012 · 135 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17